Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study

dc.contributor.authorDohmann, Hans F R
dc.contributor.authorSilva, Suzana A
dc.contributor.authorSousa, André L S
dc.contributor.authorBraga, Alcione M S
dc.contributor.authorCastelo Branco, Rodrigo V
dc.contributor.authorHaddad, Andréa F
dc.contributor.authorOliveira, Mônica A
dc.contributor.authorMoreira, Rodrigo C
dc.contributor.authorTuche, Fabio A A
dc.contributor.authorPeixoto, Cíntia M
dc.contributor.authorTura, Bernardo R
dc.contributor.authorBorojevic, Radovan
dc.contributor.authorRibeiro, Jorge P
dc.contributor.authorNicolau, José C
dc.contributor.authorNóbrega, Antonio C
dc.contributor.authorCarvalho, Antonio C C
dc.date.accessioned2023-12-22T12:37:25Z
dc.date.available2023-12-22T12:37:25Z
dc.date.issued2008
dc.description.abstractBackground: Myocardial infarction remains as a major cause of mortality worldwide and a high rate of survivors develop heart failure as a sequel, resulting in a high morbidity and elevated expenditures for health system resources. We have designed a multicenter trial to test for the efficacy of autologous bone marrow (ABM) mononuclear cell (MC) transplantation in this subgroup of patients. The main hypothesis to be tested is that treated patients will have a significantly higher ejection fraction (EF) improvement after 6 months than controls. Methods: A sample of 300 patients admitted with ST elevation acute myocardial infarction (STEMI) and left ventricle (LV) systolic dysfunction, and submitted to successful mechanical or chemical recanalization of the infarct-related coronary artery will be selected for inclusion and randomized to either treated or control group in a double blind manner. The former group will receive 100 x 106 MC suspended in saline with 5% autologous serum in the culprit vessel, while the latter will receive placebo (saline with 5% autologous serum). Implications: Many phase I/II clinical trials using cell therapy for STEMI have been reported, demonstrating that cell transplantation is safe and may lead to better preserved LV function. Patients with high risk to develop systolic dysfunction have the potential to benefit more. Larger randomized, double blind and controlled trials to test for the efficacy of cell therapies in patients with high risk for developing heart failure are required. Trial register: This trial is registered at the NIH registry under the number NCT00350766
dc.identifier.citationDohmann HF, Silva SA, Sousa AL, Braga AM, Branco RV, Haddad AF, Oliveira MA, Moreira RC, Tuche FA, Peixoto CM, Tura BR, Borojevic R, Ribeiro JP, Nicolau JC, Nóbrega AC, Carvalho AC. Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study. Trials. 2008 Jul 3;9:41. doi: 10.1186/1745-6215-9-41.
dc.identifier.otherDOI: 10.1186/1745-6215-9-41
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/386
dc.language.isoen
dc.publisherTrials
dc.titleMulticenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Dohmann HFR et al_Trials.pdf
Tamanho:
268.99 KB
Formato:
Adobe Portable Document Format
Descrição:
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição: